SATB2-Associated Syndrome

SATB2-associated syndrome is an autosomal dominant neurodevelopmental disorder caused by loss of one copy of SATB2 (2q33.1), with severe speech impairment, intellectual disability, cleft palate and dental anomalies. It is usually de novo, and a distinct clinical picture helps recognition.

Pathophysiology. SATB2 is a chromatin binding transcription factor for cortical neuron identity and for craniofacial and bone development. Haploinsufficiency, through variants or deletions, impairs these processes.

Speech is absent or minimal in most patients, even when comprehension is better.

Low bone density and fractures are recognised and need attention.

• Absent or markedly limited speech with relatively better receptive language
• Intellectual disability of moderate to severe degree
• Cleft palate or high arched palate, and velopharyngeal insufficiency
• Dental anomalies: crowding, macrodontia, abnormal roots, delayed eruption, fused teeth
• Behavioural issues: autism spectrum features, hyperactivity, aggression, sleep disturbance
• Hypotonia and feeding difficulties in infancy
• Low bone density and fractures, and scoliosis
• Seizures in a minority
• Gastrointestinal symptoms: constipation, reflux

• Chromosomal microarray (2q33.1 deletions) and SATB2 sequencing with deletion and duplication analysis.
• Dental examination and panoramic radiograph.
• Bone density assessment (DXA scan) and vitamin D level.
• Speech and palate assessment, including nasendoscopy.
• Brain MRI and EEG if seizures or regression.
• Developmental and behavioural assessment.

• Cleft palate: surgical repair in infancy, with speech therapy and surgery for persistent velopharyngeal insufficiency.
• Communication: early augmentative and alternative communication (sign, picture or electronic aids) without waiting for speech, plus speech and language therapy.
• Dental care: regular review with dental imaging, orthodontic planning, and extraction or restoration of abnormal teeth under general anaesthesia where needed.
• Bone health: vitamin D 600 to 1000 units daily (maintain level at 50 nmol/L or more), calcium intake of 1000 mg daily, weight bearing activity, and a bisphosphonate in selected patients with fractures (zoledronic acid 0.025 to 0.05 mg/kg intravenously every 6 months in children, specialist care).
• Behaviour and sleep: behavioural therapy, melatonin 2 to 5 mg orally 30 to 60 minutes before bed (up to 10 mg if needed), and methylphenidate 5 mg once or twice daily increasing to a maximum of 60 mg daily for ADHD.
• Gastrointestinal care: macrogol 0.4 to 0.8 g/kg daily (adults 1 to 3 sachets) for constipation, and omeprazole 0.7 to 1 mg/kg daily for reflux.
• Seizures: levetiracetam 10 mg/kg twice daily increasing to 30 mg/kg twice daily.
• Development: early intervention, occupational therapy and special education.
• Genetic counselling: de novo variants carry a low recurrence risk, with a small risk of germline mosaicism.

Special groups.

• Infants with cleft palate: feeding support with special teats and early dietetic input.

Monitoring. Development and behaviour every 6 months. Dental review every 6 months, bone density and vitamin D yearly, and audiology yearly.

Referral and escalation. Refer to clinical genetics, craniofacial surgery, speech and language therapy and a paediatric dental service. Urgent for fractures with minimal trauma, seizures, or severe self-injury.